Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting

NEW YORK, Sept. 14, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Company sponsored an industry symposium at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Munich, Germanythe largest international forum for minimally invasive image-guided therapy, with more than 5,600 interventional radiologists in attendance.

The event, held Tuesday, September 13th, was moderated by Dr. Riccardo LencioniAssociate Professor of Radiology and Head of Diagnostic Imaging and Intervention in the Department of Liver Transplantation, Hepatology and Infectious Diseases of the University of Pisa, and featured presentations by three U.S. physicians with direct experience with chemosaturation from the Company’s Phase 3 Trial:

• Jonathan Zager, MD Associate Professor of Surgery in the Cutaneous Oncology and Sarcoma Departments at the Moffitt Cancer Center Evolution, Concepts and Utility for Patients with Liver Cancer
• James R. Pingpank,MD Division of Surgical Oncology at the University of Pittsburgh Medical Center and Principal Investigator on the phase 3 trial of chemosaturation via (PHP) device - Summary of Phase 3 Clinical Trial Results
• Fred Moeslein, MD Assistant Professor of Diagnostic Radiology and Nuclear Medicine at the University of Maryland Medical Center - Practical Experience with Chemosaturation

Commenting on the announcement, Eamonn P. Hobbs, President & CEO of Delcath, said, “This session was an opportunity to present detailed information on the clinical evidence and conceptual framework for chemosaturation to a broad audience of EU-based interventional radiologists. Attendance at the session exceeded the room’s capacity. We believe this level of participationcombined with the favorable response to the positive Phase 2 data in neuroendocrine tumors presented earlier this weekis evidence of growing interest in chemosaturation among physicians in Europe.”

About Delcath Systems

Delcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath’s proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company’s initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company’s website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver including neuroendocrine tumors, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company’s NDA by the FDA, approval of the Company’s NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to obtain regulatory approval in foreign markets and adoption and use of the chemosaturation system in such markets, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

SOURCE Delcath Systems, Inc.